Evidence map›Paper›PMID 37476896›Full record

ArticleTurkish journal of medical sciences2023

Expression of dual-specificity phosphatases in TGFß1-induced EMT in SKOV3 cells.

Sabire Güler, Abdullah Yalçın

Open access · bronzeAbstract read
In one paragraph

Article in Turkish journal of medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sabire GülerDepartment of Histology and Embryology, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkey.
Abdullah YalçınDepartment of Biochemistry, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkey.
Bursa Uludağ Üni̇versi̇tesi̇ · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe study aims to profile the dual-specificity phosphatases (DUSP) expression in response to Transforming growth factor β1 (TGFβ1)-induced epithelial- mesenchymal transition (EMT) in ovarian adenocarcinoma cells.

methodsThe ovarian adenocarcinoma cell line SKOV3 was used as a TGFβ1-induced EMT model. Cells were incubated with 5 ng/mL TGFβ1 to induce EMT. EMT was confirmed with real-time qPCR, western blot, and immunofluorescence analyses of various EMT markers. Western blot was used to analyze phospho- and total MAPK protein levels. Typical and atypical DUSPs mRNA expression profile was determined by real-time qPCR.

resultsThe epithelial marker E-cadherin expressions were decreased and mesenchymal EMT markers Snail and Slug expression levelswere increased after TGFβ1 induction. Phosphorylation of ERK1/2 and p38 MAPK were enhanced in response to TGFβ1 treatment. The expression of DUSP2, DUSP6, DUSP8, DUSP10, and DUSP13 were decreased while DUSP7, DUSP16, DUSP18, DUSP21, and DUSP27 were increased by TGFβ1. DISCUSSION: TGFβ1 induced EMT which was accompanied by increased activity of MAPKs, and led to marked changes in expressions of several DUSPs in SKOV3 cells.

Indexed as

AdenocarcinomaEpithelial-Mesenchymal TransitionCell LineDual-Specificity PhosphatasesEpithelial CellsHumansMitogen-Activated Protein Kinase PhosphatasesTransforming Growth Factor beta1Dual-Specificity PhosphatasesDUSP10 protein, humanDUSP18 protein, humanDUSP7 protein, humanMitogen-Activated Protein Kinase PhosphatasesTransforming Growth Factor beta1Dual-specificity phosphatasesepithelial-mesenchymal transitionMAPKovarian carcinomaSKOV3TGFß1

Identifiers

PMID37476896
PMCPMC10387886
OpenAlexW4381623435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.